DGAP-News
520
0 Kommentare
Biotest AG: Managers of Italian Subsidiary have been charged with illegal price fixing
520 
0 KommentareDGAP-News: Biotest AG / Key word(s): Legal Matter
Biotest AG: Managers of Italian Subsidiary have been charged with
illegal price fixing
17.11.2014 / 11:30
---------------------------------------------------------------------
PRESS RELEASE
Managers of Italian Subsidiary have been charged with illegal
price fixing
Dreieich, November 17, 2014. In 2010 the public prosecutor of Naples had
initiated investigations against numerous employees of various
pharmaceutical companies and institutions and charged them with illegal
price fixing. Besides the Director of Administration of the University of
Naples and the owner of an Italian pharmaceutical wholesaler now also three
managers of Biotest Italia Srl, a 100% subsidiary of Biotest AG, are
concerned. Biotest AG is not aware of any of such alleged practices and
strongly condemns such methods which are not in line with our Pharma Codex
and our compliance rules. According to Biotest Italia Srl the company is
closely cooperating with the investigating authorities. Biotest AG has
retained an independent audit firm to internally investigate the case.
In some media reports about the case it is claimed that Biotest Italia Srl
had sold ineffective drugs or preparations without valid market
authorization. Biotest decisively rejects as incorrect both claims. The
preparations of Biotest are efficacious, safe and fully licensed by the
authorities.
Disclaimer
This document contains forward-looking statements on overall economic
development as well as on the business, earnings, financial and assets
position of Biotest AG and its subsidiaries. These statements are based on
current plans, estimates, forecasts and expectations of the company and are
thus subject to risks and elements of uncertainty that could result in
significant deviation of actual developments from expected developments.
The forward-looking statements are only valid at the time of publication.
Biotest does not intend to update the forward-looking statements and
assumes no obligation to do so.
About Biotest
Biotest is a provider of plasma proteins and biological drugs. With a value
added chain that extends from pre-clinical and clinical development to
worldwide sales, Biotest has specialised primarily in the areas of clinical
immunology, haematology and intensive medicine. Biotest develops and
markets immunoglobulins, coagulation factors and albumins based on human
blood plasma. These are used for diseases of the immune and haematopoietic
systems. In addition Biotest develops monoclonal antibodies in the
indications of rheumatoid arthritis and cancer of plasma cells, which are
produced by recombinant technologies. Biotest has more than 2.100 employees
worldwide. The preference shares of Biotest AG are listed in the SDAX on
the Frankfurt stock exchange.
Biotest AG, Landsteinerstr. 5, 63303 Dreieich, www.biotest.de
Dr. Monika Buttkereit
tel.: +49 (0) 6103 801-4406,
e-mail: investor_relations@biotest.de
fax: +49 (0) 6103 801-347
Securities' ID No., ISIN ordinary shares: 522720, DE0005227201
Securities' ID No., ISIN preference shares: 522723, DE0005227235
Listing: Prime Standard
Open Market: Berlin-Bremen, Düsseldorf, Frankfurt, Hamburg, Hannover,
München, Stuttgart
---------------------------------------------------------------------
17.11.2014 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: Biotest AG
Landsteinerstraße 5
63303 Dreieich
Germany
Phone: 0 61 03 - 8 01-0
Fax: 0 61 03 - 8 01-150
E-mail: investor_relations@biotest.de
Internet: http://www.biotest.de
ISIN: DE0005227235, DE0005227201
WKN: 522723, 522720
Indices: SDAX
Listed: Regulierter Markt in Frankfurt (Prime Standard);
Freiverkehr in Berlin, Düsseldorf, Hamburg, Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------
297521 17.11.2014
PRESS RELEASE
Managers of Italian Subsidiary have been charged with illegal
price fixing
Dreieich, November 17, 2014. In 2010 the public prosecutor of Naples had
initiated investigations against numerous employees of various
pharmaceutical companies and institutions and charged them with illegal
price fixing. Besides the Director of Administration of the University of
Naples and the owner of an Italian pharmaceutical wholesaler now also three
managers of Biotest Italia Srl, a 100% subsidiary of Biotest AG, are
concerned. Biotest AG is not aware of any of such alleged practices and
strongly condemns such methods which are not in line with our Pharma Codex
and our compliance rules. According to Biotest Italia Srl the company is
closely cooperating with the investigating authorities. Biotest AG has
retained an independent audit firm to internally investigate the case.
In some media reports about the case it is claimed that Biotest Italia Srl
had sold ineffective drugs or preparations without valid market
authorization. Biotest decisively rejects as incorrect both claims. The
preparations of Biotest are efficacious, safe and fully licensed by the
authorities.
Disclaimer
This document contains forward-looking statements on overall economic
development as well as on the business, earnings, financial and assets
position of Biotest AG and its subsidiaries. These statements are based on
current plans, estimates, forecasts and expectations of the company and are
thus subject to risks and elements of uncertainty that could result in
significant deviation of actual developments from expected developments.
The forward-looking statements are only valid at the time of publication.
Biotest does not intend to update the forward-looking statements and
assumes no obligation to do so.
About Biotest
Biotest is a provider of plasma proteins and biological drugs. With a value
added chain that extends from pre-clinical and clinical development to
worldwide sales, Biotest has specialised primarily in the areas of clinical
immunology, haematology and intensive medicine. Biotest develops and
markets immunoglobulins, coagulation factors and albumins based on human
blood plasma. These are used for diseases of the immune and haematopoietic
systems. In addition Biotest develops monoclonal antibodies in the
indications of rheumatoid arthritis and cancer of plasma cells, which are
produced by recombinant technologies. Biotest has more than 2.100 employees
worldwide. The preference shares of Biotest AG are listed in the SDAX on
the Frankfurt stock exchange.
Biotest AG, Landsteinerstr. 5, 63303 Dreieich, www.biotest.de
Dr. Monika Buttkereit
tel.: +49 (0) 6103 801-4406,
e-mail: investor_relations@biotest.de
fax: +49 (0) 6103 801-347
Securities' ID No., ISIN ordinary shares: 522720, DE0005227201
Securities' ID No., ISIN preference shares: 522723, DE0005227235
Listing: Prime Standard
Open Market: Berlin-Bremen, Düsseldorf, Frankfurt, Hamburg, Hannover,
München, Stuttgart
---------------------------------------------------------------------
17.11.2014 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: Biotest AG
Landsteinerstraße 5
63303 Dreieich
Germany
Phone: 0 61 03 - 8 01-0
Fax: 0 61 03 - 8 01-150
E-mail: investor_relations@biotest.de
Internet: http://www.biotest.de
ISIN: DE0005227235, DE0005227201
WKN: 522723, 522720
Indices: SDAX
Listed: Regulierter Markt in Frankfurt (Prime Standard);
Freiverkehr in Berlin, Düsseldorf, Hamburg, Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------
297521 17.11.2014
Diskutieren Sie über die enthaltenen Werte
Aktuelle Themen
Weitere Artikel des Autors
Verfasst von EQS Group AG
URL kopieren
Per E-Mail teilen
Artikel drucken1 im Artikel enthaltener WertIm Artikel enthaltene Werte
Artikel zu den Werten
Auch bei Lesern beliebt
